Skip to search formSkip to main contentSkip to account menu

Elacridar

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2013
Highly Cited
2013
Elacridar (ELC) and tariquidar (TQD) are generally thought to be nontransported inhibitors of P-glycoprotein (Pgp) and breast… 
Highly Cited
2012
Highly Cited
2012
Sunitinib is an orally active, multitargeted tyrosine kinase inhibitor which has been used for the treatment of metastatic renal… 
Highly Cited
2009
Highly Cited
2009
Purpose: Imatinib, a BCR-ABL tyrosine kinase inhibitor, is a substrate of the efflux transporters P-glycoprotein (P-gp; ABCB1… 
Highly Cited
2008
Highly Cited
2008
Highly Cited
2008
Highly Cited
2007
Highly Cited
2007
Purpose: Breast cancer resistance protein (ABCG2) substantially limits the oral bioavailability of topotecan. Coadministration… 
Highly Cited
2005
Highly Cited
2005
Imatinib mesylate (signal transduction inhibitor 571, Gleevec) is a potent and selective tyrosine kinase inhibitor, which was… 
Highly Cited
2003
Highly Cited
2003
P-Glycoprotein (Pgp) in the blood-brain barrier limits the uptake of substrate drugs into the brain. We have determined the…